Auckland Radiation Oncology Selected the
Latest-Generation CyberKnife S7™ System to Deliver Precise
Treatments More Quickly, so Patients Can Rapidly Return to the
Activities They Enjoy
SUNNYVALE, Calif., Jan. 17,
2023 /PRNewswire/ -- Accuray Incorporated (NASDAQ:
ARAY) announced today that Auckland Radiation Oncology (ARO) is the
first center in New Zealand to
treat patients with the CyberKnife® System, a robotic
radiation therapy device known for delivering treatments with
sub-millimeter precision and accuracy in typically 1 to 5
outpatient sessions. The ARO medical care team selected the
latest generation CyberKnife S7™ System to provide stereotactic
radiosurgery (SRS) and stereotactic body radiation therapy (SBRT)
to patients more efficiently, minimizing the time they spend in
daily treatments and maximizing the number of New Zealand cancer patients they can treat
each day.
"These first-in-country patient treatments reinforce the value
the CyberKnife System provides to medical care teams around the
globe. The addition of the Auckland Radiation Oncology center to
the network of facilities using the CyberKnife System will broaden
access to a trusted radiation therapy treatment option," said
Suzanne Winter, president and CEO of
Accuray. "We believe the system has the ability to significantly
and positively impact the way the Auckland Radiation Oncology team
treats cancer and certain neurological conditions, and will enable
them to bring new hope to people who previously would have been
without options."
The CyberKnife S7 System combines speed, precision and motion
synchronization technology for the treatment of lesions and tumors
throughout the body. Treatment is non-surgical, non-invasive and
does not require incisions or general anesthesia. Clinical studies
support the use of the CyberKnife System, expanding medical care
team options for achieving outstanding outcomes for a wide range of
indications.
ARO Clinical Director Dr. Benji
Benjamin said, "We believe the CyberKnife System is more
accurate than traditional radiation therapy, with potentially
thousands of smaller beams delivering radiation to the tumor with
sub-millimeter precision, minimizing damage to surrounding healthy
structures and organs. Introducing the system to our suite of tools
is about giving New Zealanders access to one of the world's most
advanced treatment options and doing what we can to minimize the
impact of an already challenging time in people's lives."
Dr. Ian Hanson, ARO's Chief
Physicist, added, "During treatment, the CyberKnife System will
detect any movement of the patient or the tumor and will
automatically move the robot to ensure that the cancer is always
precisely targeted. This allows for higher doses of radiation to be
delivered to the tumor each day, substantially shortening overall
treatment times while minimizing the likelihood of unwanted side
effects.
"For example, instead of up to 20 rounds of radiation over four
weeks for prostate cancer, with the CyberKnife, patients will
likely only need one week of highly targeted treatment. This could
be game changing for New Zealand
men."
Click here to learn more about the CyberKnife S7 System at
Auckland Radiation Oncology.
Important Safety Information
For Important Safety Information please refer to
https://www.accuray.com/safety-statement.
About Auckland Radiation Oncology
Auckland Radiation Oncology is a joint venture, owned and operated
by MercyAscot and Southern Cross Healthcare. Established in 2008 as
the first private radiation therapy treatment centre in
New Zealand, Auckland Radiation
Oncology treats 70-100 patients daily requiring radiation therapy,
from its purpose-built treatment centre in Epsom, Auckland. With an international reputation for
being at the forefront of radiation therapy cancer treatment,
Auckland Radiation Oncology offers patients a choice of
leading-edge radiation therapy aimed directly at improving cancer
treatment outcomes and quality of life.
About Accuray
Accuray is committed to expanding the powerful potential of
radiation therapy to improve as many lives as possible. We invent
unique, market-changing solutions that are designed to deliver
radiation treatments for even the most complex cases—while making
commonly treatable cases even easier—to meet the full spectrum of
patient needs. We are dedicated to continuous innovation in
radiation therapy for oncology, neuro-radiosurgery, and beyond, as
we partner with clinicians and administrators, empowering them to
help patients get back to their lives, faster. Accuray is
headquartered in Sunnyvale,
California, with facilities worldwide. To learn more, visit
www.accuray.com or follow us on Facebook, LinkedIn,
Twitter, and YouTube.
Safe Harbor Statement
Statements made in this press release that are not statements of
historical fact are forward-looking statements and are subject to
the "safe harbor" provisions of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements in this press
release relate, but are not limited, to clinical applications,
clinical results, patient experiences and patient outcomes. These
forward-looking statements involve risks and uncertainties. If any
of these risks or uncertainties materialize, or if any of the
company's assumptions prove incorrect, actual results could differ
materially from the results expressed or implied by these
forward-looking statements. These risks and uncertainties include,
but are not limited to, the company's ability to achieve widespread
market acceptance of its products, including new product
innovations and releases; the company's ability to develop new
products or improve existing products to meet customers' needs; the
company's ability to anticipate or keep pace with changes in the
marketplace; and the direction of technological innovation and
customer demands and such other risks identified under the heading
"Risk Factors" in the company's Quarterly Report on Form 10-Q,
filed with the Securities and Exchange Commission (the "SEC") on
November 3, 2022, and as updated
periodically with the company's other filings with the SEC.
Forward-looking statements speak only as of the date the
statements are made and are based on information available to the
company at the time those statements are made and/or management's
good faith belief as of that time with respect to future events.
The company assumes no obligation to update forward-looking
statements to reflect actual performance or results, changes in
assumptions or changes in other factors affecting forward-looking
information, except to the extent required by applicable securities
laws. Accordingly, investors should not put undue reliance on any
forward-looking statements.
Media Contact:
Beth
Kaplan
Public Relations Director,
Accuray
+1 (408)
789-4426
bkaplan@accuray.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/accuray-announces-first-patient-treatments-in-new-zealand-with-the-cyberknife-system-the-worlds-only-robotic-radiation-therapy-delivery-device-301722612.html
SOURCE Accuray Incorporated